JPMorgan Chase & Co. lowered shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from an overweight rating to a neutral rating in a report released on Thursday morning, Marketbeat.com reports.

Other equities research analysts also recently issued research reports about the company. TheStreet raised Enanta Pharmaceuticals from a c+ rating to a b- rating in a research report on Wednesday, December 13th. Royal Bank of Canada reiterated a buy rating and issued a $54.00 target price on shares of Enanta Pharmaceuticals in a report on Friday, October 20th. Finally, Zacks Investment Research cut Enanta Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, January 30th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $51.25.

Shares of Enanta Pharmaceuticals (NASDAQ ENTA) opened at $73.42 on Thursday. The company has a market capitalization of $1,410.00, a price-to-earnings ratio of 44.50 and a beta of 1.04. Enanta Pharmaceuticals has a 1 year low of $27.24 and a 1 year high of $95.91.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the Zacks’ consensus estimate of $2.13 by ($0.27). The business had revenue of $75.93 million during the quarter, compared to analysts’ expectations of $73.80 million. Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.33%. Enanta Pharmaceuticals’s revenue for the quarter was up 491.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.09) EPS. analysts predict that Enanta Pharmaceuticals will post 0.86 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. boosted its holdings in Enanta Pharmaceuticals by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 53,616 shares of the biotechnology company’s stock valued at $1,930,000 after acquiring an additional 304 shares during the last quarter. Thrivent Financial For Lutherans boosted its holdings in Enanta Pharmaceuticals by 7.3% in the second quarter. Thrivent Financial For Lutherans now owns 8,410 shares of the biotechnology company’s stock valued at $303,000 after acquiring an additional 570 shares during the last quarter. Parametric Portfolio Associates LLC boosted its holdings in Enanta Pharmaceuticals by 7.9% in the second quarter. Parametric Portfolio Associates LLC now owns 12,787 shares of the biotechnology company’s stock valued at $460,000 after acquiring an additional 933 shares during the last quarter. Voya Investment Management LLC boosted its holdings in Enanta Pharmaceuticals by 13.3% in the second quarter. Voya Investment Management LLC now owns 8,350 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 977 shares during the last quarter. Finally, Eqis Capital Management Inc. boosted its holdings in Enanta Pharmaceuticals by 3.3% in the fourth quarter. Eqis Capital Management Inc. now owns 31,099 shares of the biotechnology company’s stock valued at $1,825,000 after acquiring an additional 997 shares during the last quarter. Hedge funds and other institutional investors own 67.86% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://theolympiareport.com/2018/02/12/enanta-pharmaceuticals-enta-cut-to-neutral-at-jpmorgan-chase-co.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.